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Case definitionPreterm birth is commonly defined as any birth before 37 weeks completed weeks of gestation. An esti-
mated 15 million infants are born preterm globally, disproportionately affecting low and middle income
countries (LMIC). It contributes directly to estimated one million neonatal deaths annually and is a sig-
nificant contributor to childhood morbidity. However, in many clinical settings, the information available
to calculate completed weeks of gestation varies widely. Accurate dating of the last menstrual period
(LMP), as well as access to clinical and ultrasonographic evaluation are important components of gesta-
tional age assessment antenatally. This case definition assign levels of confidence to categorisation of
births as preterm, utilising assessment modalities which may be available across different settings.
These are designed to enable systematic safety evaluation of vaccine clinical trials and post-
implementation programmes of immunisations in pregnancy.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Preamble
1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for preterm birth as an adverse
event following immunisation
Preterm birth has been defined as any birth before 37 weeks
completed weeks of gestation. An estimated 15 million infants
6048 J.-A. Quinn et al. / Vaccine 34 (2016) 6047–6056are born preterm, with resulting complications. It is the principal
cause of an estimated one million neonatal deaths annually and
a significant contributor to childhood morbidities. Low and middle
income countries (LMIC) carry a higher burden of disease attribu-
ted to preterm birth.
The World Health Organisation (WHO) defines preterm birth as
any birth before 37 completed weeks of gestation, or fewer than
259 days since the first day of the woman’s last menstrual period
(LMP). This is further subdivided on the basis of gestational age
(GA):
 extremely preterm (<28 weeks);
 very preterm (28–<32 weeks);
 moderate or late preterm (32–<37 completed weeks of
gestation).
This is the most extensively used and accepted definition of pre-
term birth [1].
The ability to accurately determine the completed weeks of ges-
tation varies widely between pregnancies, with the most precise
assessment methods not uniformly available across different set-
tings. Vaccination in pregnancy has been widely implemented to
protect women and their babies from tetanus and pertussis in
recent years, with an increasing number of vaccines being devel-
oped and trialled for use in pregnancy against a variety of bacterial
and viral infections. As preterm birth is such an important preg-
nancy outcome that may represent an adverse event, it is important
to establish a case definition for use across vaccine studies and post-
licensure surveillance that is able to make use of all methodologies
used to calculate gestational age, and that incorporates a hierarchy
based upon the precision of the various methods used.
The nomenclature of GA is typically discussed in terms of the
number of completed weeks (e.g., 33 weeks and 2 days, or 33 2/7
weeks). Defining GA has been considered useful in terms of neona-
tal outcome. In the past, three groups have been classified and uti-
lised according to delivery following the onset of the last menstrual
period. Pre-term: less than 259 days (37 weeks), term: 259–293
days (37–41 weeks). Post-term: 294 days (42 weeks) or more.
A term birth has been defined as between 37 and 42 weeks and
used to describe the optimal timing for a good outcome for the
mother and baby. The International Classification of Diseases
defines term pregnancy as a delivery from 37 completed weeks
to less than 42 completed weeks (259–293 days) of gestation.
However, neonatal outcomes vary within this wide gestational
age range, with a 2012 international stakeholder working group
recommending sub-categorisation of term birth to more accurately
describe deliveries and their outcomes. These sub-categories are:
early term (37 0/7 weeks of gestation through 38 6/7 weeks gesta-
tion); full term (39 0/7 weeks of gestation through 40 6/7 weeks of
gestation); late term (41 0/7 weeks of gestation through 41 6/7
weeks of gestation); and, post term (42 0/7 weeks of gestation
and beyond). The American College of Obstetricians and Gynaecol-
ogists (ACOG) and the Society for Maternal–Foetal Medicine
(SMFM) has endorsed this recommendation and encourages its
use for categorising GA [2–5].
1.1.1. Pathophysiology of preterm birth
Causes of preterm birth are complex and the pathophysiology
that triggers preterm birth is largely unknown, however, contribut-
ing maternal, foetal and placental predisposing factors have been
identified. The most common of these include: antepartum haem-
orrhage or abruption; mechanical factors such as uterine over-
distention and cervical incompetence; hormonal changes; and,
bacterial infection and inflammation [6,7].
Over the past 20 years the access to assisted reproduction tech-
nology (ART) in many high income countries has contributed to therise in the number of multiple births and an overall increase in the
rates of preterm delivery. Infants born from multiple pregnancies
are more likely to be born preterm due to spontaneous labour or
premature rupture of membranes (PROM), or as a result of mater-
nal conditions such as pre-eclampsia or foetal disorders [8,9].
Changes to policies which limit the number of embryos implanted
as part of ART have led to a decline in the number of preterm births
due to assisted fertility [10,11].
Epidemiologic studies have identified preterm birth risk factors
as maternal age of less than 17 years or more than 35 years, being
underweight, having an overweight pre-pregnancy body mass
index, and short stature. Preterm birth rates vary geographically
and within ethnic origins, with LMIC consistently having higher
rates [7,12]. Physical and psychosocial stress and smoking have
also been associated with higher preterm risk as does a previous
preterm birth.
The assessment and diagnosis of preterm birth has remained
problematic since it is not a defined disease and the WHO defini-
tion does not contain universally recognised reference standards.
Different methodologies are used for assessing GA and because
reporting rates vary widely between and within countries, accurate
comparison of reporting rates of preterm birth and trending data is
difficult to analyse [13–17].
1.1.2. Preterm birth categorisation
Preterm birth defined as less than 37 completed weeks encom-
passes a wide gestational age range with rates varying across coun-
tries. The WHO subcategories of ‘extremely preterm’, ‘very
preterm’ and ‘moderate or late preterm’ are recommended to
improve comparability of preterm birth data in relation to
immunisation.
A limitation of the WHO definition is that there is no boundary
between spontaneous abortion and a viable birth, complicating the
assessment of preterm birth in the extremely preterm group of
babies. A comparison between and within countries becomes com-
plex with varying gestational lower limits of viability over time and
across different settings. Determining a lower limit is complex as it
is variably defined and arbitrary. It is often described in terms of risk
factors and its causes, and is predominately developed according to
postnatal viability and data quality in different settings [17–20].
Preterm births are reported only for live born infants. The preg-
nancy outcomes differ across countries where the upper limit for
national or regional criteria for registration of a foetal death range
from 16 weeks to 28 weeks, this impacting on the proportion of
preterm births [21].
The registrations of births in LMIC often do not routinely record
GA and the data on birthweight (BW) is often not recorded or com-
piled. It has been reported that 58% of babies in these countries are
not weighed at birth and home based births are not represented
[20,22,23].
1.1.3. Preterm birth following immunisation: what is known in
literature?
Pregnant women are at increased risk of morbidity and mortal-
ity and adverse pregnancy outcomes, including preterm birth, due
to vaccine preventable diseases. Vaccination in pregnancy is a
recognised preventive measure for protecting the mother, foetus
and infant [24–27].
Until the 1960s vaccines, including polio, influenza, diphtheria
and tetanus toxoid vaccines, were routinely administered to preg-
nant women in maternal immunisation programmes. Studies in a
variety of developed settings detected no increase in adverse con-
sequences for the mother or foetus in vaccinated women [28,29].
However, the thalidomide teratogenicity disaster in pregnant
women resulted in widespread concerns about the safety of all
medicine use in pregnancy, including vaccines. Vaccines were then
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pregnancy to prevent any attribution of teratogenicity risk, as well
as to minimise the potential risk to the course of normal gestation
such as induction of premature labour [30,31].
Over recent decades, with further development of safe and
immunogenic vaccines, as well as improved ability to explore preg-
nancy outcome datasets, ongoing studies have provided important
information on vaccine safety. Immunisation with inactivated vac-
cines and toxoids during pregnancy has not been associated with
any increased risk to the mother or baby. The extensive use of Teta-
nus Toxoid (TT) and Tetanus diphtheria (Td) in pregnant women, to
prevent neonatal tetanus, has shown no clinically significant
adverse events and no adverse pregnancy outcomes for women
who have received the Tetanus, diphtheria, acellular pertussis
(Tdap) vaccine during pregnancy [32–34].
The US Advisory Committee on Immunisation Practices (ACIP)
in 2012 updated their recommendations to providers of prenatal
care to implement a Tdap immunisation programme for all preg-
nant women to reduce the burden of pertussis in infants. Its rec-
ommendation is for its use with every pregnancy. Similarly, in
October 2012, the United Kingdom Department of Health recom-
mended a temporary Tdap programme in pregnancy in response
to an outbreak [35–38]. An observational cohort study linking
more than 20,000 vaccinated women with pregnancy outcomes
showed no increase in stillbirth or other major complications,
including preterm birth [39]. Immunisation of pregnant women
with inactivated trivalent influenza vaccine has also been recom-
mended and endorsed for more than a decade showing no increase
in adverse events. Pregnant women who received H1N1 influenza
vaccine during the 2009 H1N1 influenza pandemic were in fact less
likely to give birth preterm [40,41–47].
Live viral vaccines, such as measles, mumps, rubella (MMR);
varicella; intranasal live-attenuated influenza; Yellow Fever, and
BCG however are contraindicated and not recommended during
pregnancies, with a theoretical risk that the vaccine virus could
be transmitted to the foetus [48]. Follow up of inadvertent vaccina-
tions of pregnant women with live vaccines have not demon-
strated significant adverse effects but these limited data have not
been sufficient to change recommendations. The risk benefit to
the mother and neonate needs to be taken into account.
1.1.4. Existing case definitions for preterm birth
Historically, preterm birth was determined using neonatal
physical examination, reviewing clinical history and socio-
demographics [49,50]. Early definitions of prematurity relied on
BW, using a birth weight category of less than 2300 or 2500 g.
One of the earliest working definitions was introduced by the
World Health Assembly (WHA) in 1948 using a birth weight of
2500 g (5 pounds, 8 ounces) or less as a determinant [49].
Early epidemiological studies of prematurity tended to include
all low birth weight babies irrespective of gestation. BW was used
as a criterion alone as it was objective, easily measured, and the
survival of the very low birth weight (VLBW) neonates was
described in birth weight specific categories [51–54]. BW however,
can only be used as a surrogate in the lower gestational age babies
where it has been identified to be a specific and sensitive method
in assessing the early preterm. Babies weighing less than 1500 g
are predominately assessed as being preterm [55,56]. The lack of
standardised birthweight categories makes it difficult to analyse
and compare data from different regions [22,57–59].
However, BW based standards for preterms are complicated by
physiological variables that occur more commonly pregnancies
complicated by preterm birth [60,61]. Preterm infants are often
growth restricted and conventional BW charts are limited as they
do not reflect the degree of growth restriction. The Foetal Growth
Longitudinal Study (FGLS), part of the INTERGROWTH-21 Projectdeveloped international growth and size standards for foetuses.
The growth standards are recommended for the clinical interpreta-
tion of ultrasound measurements and for comparisons across pop-
ulations [62]. Foetal growth standards for preterm infants will
determine the precise incidence of foetal growth restriction when
gestation is known [63–65].
The World Health Organisation (WHO) definition of preterm
birth remains the most widely utilised and accepted definition.
The International Classification of Diseases (ICD-9, ICD-10) defines
preterm birth as less than 37 completed weeks (less than 259 days)
of gestation. The duration of gestation is measured from the first
day of the LMP. GA is expressed in completed days or completed
weeks (e.g., events occurring 280–286 completed days after the
onset of the LMP are considered to have occurred at 40 weeks of
gestation). Where the date of the LMP is not available, GA is based
on the best clinical estimate [2].
A search of terminology databases, including the Global Alliance
on Prevention of Prematurity (GAPPS), the National Institutes of
Health, and the Common Terminology Criteria for Adverse Events
(CTCAE) show a consistency with the WHO definition as the onset
of labour before 37 completed weeks of pregnancy (full term is 40
completed weeks) [7,66].
Essential in any definition or the sub classification of preterm
birth is the need for accurate dating. GA has evolved as the stand
alone parameter for determining preterm birth. In 1949 the U.S.
National Centre for Health Statistics of the Centres for Disease Con-
trol and Prevention revised the World Health Assembly definition
and deleted the reference to BW, to include only the reporting of
the length of pregnancy in weeks. In 1956 this was further revised
to specify the reporting of completed weeks of gestation [67].
A 1961 report by the Expert Committee on Maternal and Child
Health of the World Health Organisation highlighted the difference
between premature and those infants of low birth weight (LBW)
and in 1970 a working party of obstetricians and paediatricians
at the Second European Congress of Perinatal Medicine set the
boundary between preterm and term birth at 37 weeks of gesta-
tion [5].
This is the basis of the most recent widely utilised and accepted
definition of prematurity [68].
Before the development of more accurate methods of estimat-
ing gestation, the LMP remains as the most widely available mea-
sure. This method is used where ultrasound (US) is not available or
accessible and is recommended by the WHO for determining pre-
term birth [12,69,70].
When available, in the clinical context, it is a valid and applica-
ble measure, especially when estimating gestation of less than or
equal to 33 weeks. Its limitations are discussed as being a determi-
nant based on self-reporting and therefore felt to be imprecise.
Studies have shown, however, that women who were certain of
their LMP were accurate in their assessment of pregnancy duration
compared with their ultrasound dating [71].
When information about the LMP is absent or uncertain, esti-
mates of gestational age can be determined from a clinical assess-
ment including the description of pregnancy symptoms such as
nausea, fatigue, tender swollen breasts, frequent urination, a pelvic
examination when performed in the first trimester and fundal
height (FH) ascertainment. One study demonstrated a high correla-
tion between early pregnancy dating up to 9 completed weeks by a
clinician based on an examination and history and that determined
by ultrasound but this is influenced by the skill and experience of
the clinician [72].
Fundal height (FH) is often used in conjunction with LMP and/or
the BW of the neonate, especially in low resource settings. Women
from many traditional societies however often do not record their
LMP date and can present late in the first trimester. Variability in
FH measurements relate to previous caesarean section (C/S),
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retardation, maternal obesity, polyhydramnios, and a difference
in examination techniques. FH measurement is not standardised
and use beyond 16 weeks reduces in accuracy, affecting its reliabil-
ity and the precision of dating [58,73,74]. Its use in combination
with more sensitive assessment methods is recommended.
Through the advent of US, the use of early home pregnancy
tests, ART such as intrauterine insemination (IUI), and home ovula-
tion test kits, the actual timing of conception can be determined
and therefore accurate dating of gestational age performed. Preg-
nancies achieved through ART represent the most accurate
method.
Outside the use of ART, an ultrasound performed in the first tri-
mester (13 6/7 weeks), is viewed as the most accurate and reli-
able measure. There has been a shift from using LMP to using US
for predicting an actual date of delivery. Estimation of the foetal
crown rump length ± biparietal diameter/femur length between
the gestational age of 6–18 weeks shows an accuracy within 5–7
days. In women with uncertain dates an early US is recommended
for optimal dating [3].
The methodology for US gestational age assessment, however, is
not standardised and tends to give a transitory increase in preterm
births when compared to the use of LMP alone. In addition, US
accessibility in LMIC is limited for the majority of women and
therefore cannot be considered a universal measure for determin-
ing preterm birth [20,57,75–78]. Defining preterm delivery for
LMIC would therefore be strengthened by the use of one or both
measures when available [4,79–83].
Where measurements such as LMP, US or antenatal clinical
assessment are absent or likely to be inaccurate, a recommended
criterion for determining preterm birth is a clinical estimation of
gestational age based on the physical and neurological examina-
tion of the neonate [84,85]. A review of methods used identified
tools based on neurological and physical criteria, or physical crite-
ria alone. Methods that use neurologic criteria are proven, reliable
measures with expert operators but the feasibility for use is com-
promised especially in LMIC, being limited by complexity, and
requiring skill and experience to perform [70,86–89]. Ascertain-
ment of neurologic signs and external characteristics used in the
assessment need to be precise and accurate to ensure correct cor-
relation with actual GA [51,90,91].
The physical examination based systems have been refined and
modified to improve their applicability and accuracy. Some meth-
ods now use external characteristics alone, enabling gestational
age to be determined and estimated in all settings. Using the avail-
able methods ranging in the current criteria, there is a correlation
with LMP based estimation of over 90%, but an acknowledged range
of error for predicting clinical maturity of ±2.4 weeks. Physical
examination tools alone, when used for neonates under 28–33
weeks are recognised to be inaccurate and are therefore are not rec-
ommended to be used as a measure to accurately estimate the ges-
tation of neonates within the lower limit of viability [92–97].
The Ballard Maturational Score, known as the New Ballard
Score, uses both physical and neurological assessment and has
been refined and expanded to include extremely premature neo-
nates and is described as a valid and accurate gestational assess-
ment tool [98].
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for preterm birth as an
adverse events following immunisation
Following the process described in the overview paper as well
as on the Brighton Collaboration Website http://www.brightoncol-
laboration.org/internet/en/index/process.html, the Brighton Col-
laboration Preterm Birth Working Group was formed in 2015 andincluded members of clinical, academic, public health, and indus-
try background. The composition of the working and reference
group as well as results of the web-based survey completed by
the reference group with subsequent discussions in the working
group can be viewed at: http://www.brightoncollaboration.org/in-
ternet/en/index/workinggroups.html.
To guide the decision-making for the case definition and guide-
lines, a literature search was performed using Medline, Embase,
PubMed, Cinahl, Clincal Key and the Cochrane Libraries for pub-
lished work relevant to this review with the search terms includ-
ing: ‘prematurity’; ‘preterm birth’; ‘neonatal outcomes’; ‘birth
outcomes’; ‘gestational age’; ‘premature labour’; ‘preterm deliv-
ery’; ‘spontaneous labour’; ‘antenatal’; ‘low birth weight’; ‘neonatal
mortality’; ‘stillbirth’; ‘extremely preterm’; ‘moderate preterm’;
‘late preterm’; ‘neurological assessment’; ‘vaccination’; ‘immunisa-
tion’; ‘viability’; ‘spontaneous labour’; ‘epidemiology’; ‘perinatal
outcomes’; ‘last menstrual period’; ‘LMP’; ‘ultrasound’; ‘US’; ‘preg-
nancy duration’; ‘obstetrics’; ‘morbidity’; ‘small for gestational
age’; ‘birthweight’; ‘foetal growth’; ‘multiple pregnancy’; ‘preg-
nancy’; ‘risk factors’; ‘fundal height’; and terms in combination.
We focused on work published published in English language,
but also included commonly referenced older publications. The
search resulted in the identification of references, 262 articles with
potentially relevant material were reviewed in more detail in order
to identify studies using case definitions or, in their absence, pro-
viding clinical descriptions of the case material. This review
resulted in a detailed summary of 99 articles, including informa-
tion on the diagnostic criteria or case definition put forth.
1.3. Rationale for selected decisions about the case definition of
preterm birth as an adverse event following immunisation
An ideal standardised case definition aims to improve reliability
and comparability of data collected from immunised mothers that
deliver full term or preterm infants across all health care settings. A
functional case definition is important for the evaluation and
assessment of data to help determine whether a vaccine adminis-
tered during pregnancy may or may not be implicated in a subse-
quent preterm birth. The definition must be applicable in regions
that are geographically and administratively diverse, regardless
of available health care personnel, training and resources.
There has never been a single unanimously accepted definition
of prematurity. The literature identified was notable for inconsis-
tent definitions and numerous descriptions for preterm birth.
Existing definitions categorise preterm birth by clinical presenta-
tion, BW and GA.
There is hence no uniformly accepted definition of preterm
birth that is able to be employed to evaluate its occurrence follow-
ing antenatal immunisations. This poses a missed opportunity and
a potential risk to immunisation trials and programmes as well as
pregnant women, as potential associations may be falsely raised or
dismissed without an agreed case definition. Data comparability
across a myriad of trials and varying surveillance systems would
facilitate data interpretation and improve the ability of investiga-
tors and regulators to confidently detect or rule out any association
between immunisations in pregnancy and preterm birth. The work
group recommended the use of the current definition for Preterm
Birth with the subcategories of extremely preterm, very preterm
and moderate or late preterm. Accurate dating is essential for the
definition, with GA assessment criteria implicit for categorising.
1.3.1. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
It needs to be re-emphasised that the grading of definition
levels is entirely about diagnostic certainty of the event, not its
clinical severity. Thus, a very severe clinical event, like Preterm
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than Level One, based upon the level confidence the birth truly
occurred preterm.
The amount of information, including number of symptoms
and/or signs, that will be documented for each case may vary con-
siderably. The case definition has been formulated such that the
Level 1 definition is highly specific (or confident) for preterm birth.
As maximum specificity normally implies a loss of sensitivity, two
additional diagnostic levels have been included in the definition,
offering a stepwise increase of sensitivity from Level One down
to Level Three, while retaining an acceptable level of specificity
at all levels. In this way it is hoped that all possible cases of Pre-
term Birth can be captured.
1.3.2. Precision of gestational age assessment
The most accurate methods for GA assessment are included in
Level 1 of diagnostic certainty. The GAIA Preterm Birth working
group considered that pregnant women with a certain menstrual
date or those who have undergone IUI or Embryo Transfer (ET)
with a confirmatory 1st trimester scan (13 6/7 weeks) or a 1st tri-
mester ultrasound established date (13 6/7 weeks) alone, as rep-
resenting the ‘‘gold standard” of diagnostic certainty of GA
assessment, and therefore the likelihood of preterm birth. If the
LMP date and U/S date do not correlate, defaulting to U/S for GA
assessment is required.
Where there is no 1st trimester scan or ART performed, Level 2A
of diagnostic certainty is used to describe gestational dating. With
a certain menstrual date, either a confirmatory 2nd trimester ultra-
sound established date (14 0/7 weeks to 27 6/7 weeks) or a 1st tri-
mester pelvic bimanual examination are considered the next most
precise measurement methodologies. Where there is no menstrual
date, it is recommended that the 2nd trimester ultrasound estab-
lished date be used and categorised as Level 2B.
Level 3A of diagnostic certainty represents a certain menstrual
date with a 3rd trimester scan of 28 0/7 weeks+, or a confirmatory
2nd trimester fundal height, or birth weight. Where there is no
menstrual date, a 1st trimester pelvic bimanual examination
would meet the requirement. A separate level 3B category was rec-
ommended where there is an uncertain or no menstrual date. In
this case a fundal height, or newborn physical assessment or birth
weight would meet the requirement for this level.
1.3.2.1. Timing post immunisation in pregnancy. In the absence of
existing data supporting an association between any vaccine and
preterm birth, the working group did not feel it was appropriate
to define a ‘risk window’ following vaccination during pregnancy
and subsequent possible Preterm Birth. The case definition of the
outcome (Preterm Birth) is independent from the exposure (e.g.,
immunisations). Therefore, to avoid selection bias, a restrictive
time interval from immunisation to onset of Preterm Birth has
not been included. Instead, where feasible, details of this interval
should be assessed and reported as described in the data collection
guidelines.
Further, Preterm Birth often occurs outside the controlled set-
tings of clinical trials or hospitals. In some settings it may be
impossible to obtain a clear timeline of the event, particularly in
less developed or rural settings. In order to avoid excluding such
cases, the Brighton Collaboration case definition avoids setting
arbitrary time frames.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysisand presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for management of ill
infants, children, or adults. Both were developed to improve data
comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of preterm birth
2.1. Prematurity and assessment of gestational age criteria
Definitions of terms used:
 Intrauterine insemination (IUI) – A procedure in which a fine
catheter is inserted through the cervix into the uterus to deposit
a sperm sample directly into the uterus, to achieve fertilisation
and pregnancy.
 Embryo transfer – The procedure in which one or more
embryos are placed in the uterus or fallopian tube.
 Ultrasound (U/S) [62]:
- 1st trimester (13 6/7 weeks).
- 2nd trimester scan (14 0/7–27 6/7 weeks).
- 3rd trimester (28 0/7 + weeks).
 LMP (last menstrual period) – Gestational age is calculated
from the first day of the mother’s last menstrual period.
If LMP and U/S do not correlate, default to U/S GA assessment
*Certain LMP: (LMP date + 280 days): Use LMP if within 7 days
at 14 weeks; within 14 days at 26 weeks; within 21 days
beyond 26 weeks.
*Uncertain LMP – first trimester (13 6/7 weeks by LMP): Use
the approximate date of the last menstrual period (LMP) if corrob-
orated by physical exam, or a first trimester ultrasound. If there is a
discrepancy of >7 days between the LMP and the first trimester
ultrasound, the ultrasound-established dates will take preference
over LMP for gestational age dating.
*Uncertain LMP – second trimester (14 0/7–27 6/7 weeks by
LMP): Use the approximate date of the LMP if corroborated by
physical exam including fundal height, or a second trimester ultra-
sound. If there is a discrepancy of >10 days between the LMP and
the second trimester ultrasound, the ultrasound-established dates
will take preference over LMP for gestational age dating.
*Uncertain LMP – third trimester >28 weeks – third trimester
ultrasound.
*No LMP date: If menstrual dates are unknown, the ultrasound-
established dates will be used for gestational age dating or 2nd tri-
mester fundal height and/or newborn physical examination.
 Pregnancy symptoms– nausea, fatigue, tender swollen breasts,
frequent urination.
 Antenatal Physical Examination– pelvic bimanual examina-
tion confirming enlarged uterus [63].
 Newborn Physical Examination– New Ballard Score – physi-
cal and neurological assessment – Appendix 1.
 Fundal Height(FH) in cms – Appendix 2.
 Birth Weight (BW) in grams – Appendix 2.
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Level 1: (highest level of certainty)
1. Certain LMP* or intrauterine insemination (IUI) date or
embryo transfer (ET) date with confirmatory 1st trimester
scan (13 6/7 weeks).
OR
2. 1st trimester scan (13 6/7 weeks).Level 2A
1. Certain LMP* with 2nd trimester scan (14 0/7 weeks to 27 6/7
weeks). If LMP and U/S do not correlate, default to U/S GA
assessment.
OR
2. Certain LMP* with 1st trimester physical examination.Level 2B
Uncertain LMP with 2nd trimester scan (14 0/7 weeks to 27
6/7 weeks).
Level 3A
1. Certain LMP with 3rd trimester scan – 28 0/7 weeks +.
OR
2. Certain LMP with confirmatory 2nd trimester FH.
OR
3. Certain LMP with birth weight.
OR
4. Uncertain LMP with 1st trimester physical examination.2 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.Level 3B
1. Uncertain LMP with FH.
OR
2. Uncertain LMP with newborn physical assessment.
OR
3. Uncertain LMP with Birth weight.
3. Guidelines for data collection, analysis and presentation of
preterm birth
It was the consensus of the Brighton Collaboration Working
Group for Preterm Birth to recommend the following guidelines
to enable meaningful and standardised collection, analysis, and
presentation of information about Preterm Birth. However, imple-
mentation of all guidelines might not be possible in all settings.
The availability of information may vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual report of Preterm Birth.
Also, as explained in more detail in the overview paper in this vol-
ume, these guidelines have been developed by this working group
for guidance only, and are not to be considered a mandatory
requirement for data collection, analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunisation to allow for
comparability of data, and are recommended as an addition to datacollected for the specific study question and setting. The guidelines
are not intended to guide the primary reporting of Preterm Birth to
a surveillance system or study monitor. Investigators developing a
data collection tool based on these data collection guidelines also
need to refer to the criteria in the case definition, which are not
repeated in these guidelines.
Guidelines numbers below have been developed to address data
elements for the collection of adverse event information as specified
in general drug safety guidelines by the International Conference on
Harmonization of Technical Requirements for Registration of Phar-
maceuticals for Human Use [99], and the form for reporting of drug
adverse events by the Council for International Organisations of
Medical Sciences [100]. These data elements include an identifiable
reporter and patient, one or more prior immunisations, and a
detailed description of the adverse event, in this case, Preterm Birth
following maternal immunisation. The additional guidelines have
been developed as guidance for the collection of additional informa-
tion to allow for a more comprehensive understanding of Preterm
Birth following maternal immunisation.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing the Preterm Birth as specified by country-specific
data protection law.
(3) Name and contact information of the investigator or clini-
cian responsible for the subject, as applicable.
(4) Relation to the patient (e.g., immuniser [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g., first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: gestational age and birth weight.3.1.2.2. Clinical and immunisation history. For all cases and/or all
study participants, as appropriate, the following information
regarding the immunised woman should be recorded:
(8) Past medical history, including hospitalisations, underlying
diseases/disorders, pre-immunisation signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunisation includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect (e.g., immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunisation history (i.e. previous immunisations and any
adverse event following immunisation (AEFI)), in particular
occurrence of Preterm Birth after a previous immunisation.
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For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of maternal immunisation(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g., 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunisations against the same
disease).
(13) The anatomical sites (including left or right side) of all
immunisations (e.g., vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g., intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document
(17) Clinical description of signs and symptoms of Preterm Birth
in immunised woman and newborn and if there was medical
confirmation of the event (i.e. patient seen by physician).
(18) Date/time of onset,3 first observation4 and diagnosis,5 end of
episode6 and final outcome.7
(19) Concurrent signs, symptoms, and diseases in immunised
woman and newborn.
(20) Measurement/testing
 Values and units of routinely measured parameters (e.g., tem-
perature, blood pressure) – in particular those indicating the
severity of the event.
 Method of measurement (e.g., type of thermometer, oral or
other route, duration of measurement, etc.).
 Results of laboratory examinations, surgical and/or pathological
findings and diagnoses if present.
(21) Treatment given for Preterm Birth to mother and/or new-
born, especially specify what medication and dosing, or
specific interventions.
(22) Outcome8 at last observation.3 The date and/or time of onset is defined as the time post immunisation, when the
first sign or symptom indicative for Preterm Birth occurred. This may only be possible
to determine in retrospect.
4 The date and/or time of first observation of the first sign or symptom indicative
for Preterm Birth can be used if date/time of onset is not known.
5 The date of diagnosis of an episode is the day post immunisation when the event
met the case definition at any level.
6 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
7 E.g., recovery to pre-immunisation health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
8 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalisation or results in prolongation of existing hospitalisation, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.9
(24) Exposures other than the immunisation 24 h before and
after immunisation (e.g., food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for Preterm Birth should be
until the pregnancy has been completed, but specific surveil-
lance may be further predefined based on
 Biologic characteristics of the vaccine e.g., live attenuated ver-
sus inactivated component vaccines.
 Biologic characteristics of the vaccine-targeted disease.
 Biologic characteristics of Preterm Birth including patterns
identified in previous trials (e.g., early-phase trials).
 Biologic characteristics of the vaccinee (e.g., nutrition, underly-
ing disease like immunodepressing illness).
(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with Preterm Birth should provide
guidance to reporters to optimise the quality and complete-
ness of information provided.
(30) Reports of Preterm Birth should be collected throughout the
study period regardless of the time elapsed between immu-
nisation and the adverse event. If this is not feasible due to
the study design, the study periods during which safety data
are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on Preterm Birth to allow for comparability of data,
and are recommended as an addition to data analysed for the
specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories109 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g., Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case definition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the event should be classified in additional categories four or five.
10 If the evidence available for an event is insufficient because information is
missing, such an event should be categorised as ‘‘Reported Preterm Birth with
insufficient evidence to meet the case definition”.
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(1) Level 1: Criteria as specified in the Preterm Birth case
definition.
(2) Level 2: Criteria as specified in the Preterm Birth case
definition.
(3) Level 3: Criteria as specified in the Preterm Birth case
definition.
Event does not meet case definition
Additional categories for analysis
(4) Reported Preterm Birth with insufficient evidence to meet
the case definition.11
(5) Not a case of Preterm Birth.
(32) The interval between immunisation and reported Preterm
Birth could be defined as the date/time of immunisation to
the date/time of onset12 of the newborn delivery. If few cases
are reported, the concrete time course could be analysed for
each; for a large number of cases, data can be analysed in
the following increments:
Subjects with preterm birth by interval to presentation1
fin
sh
1
re
raInterval*1 An event does not meet the case definition if investigation revea
ding of a necessary criterion (necessary condition) for diagnosis. S
ould be rejected and classified as ‘‘Not a case of Preterm Birth”.
2 Use of this document should preferably be referenced by ref
spective link on the Brighton Collaboration website (http://www.bri
tion.org).Number
<1 week after immunisation
1–<2 weeks after immunisation
2–<4 weeks after immunisation
4–<6 weeks after immunisation
4 week increments thereafter
Total(33) The duration of a possible Preterm Birth could be analysed as the interval
between the date/time of onset1 of the first symptoms and/or signs consis-
tent with the definition and the end of episode5 and/or final outcome.6
Whatever start and ending are used, they should be used consistently
within and across study groups.
(34) If more than one measurement of a particular criterion is taken and
recorded, the value corresponding to the greatest magnitude of the adverse
experience could be used as the basis for analysis. Analysis may also include
other characteristics like qualitative patterns of criteria defining the event.
(35) The distribution of data (as numerator and denominator data) could be
analysed in predefined increments (e.g., measured values, times), where
applicable. Increments specified above should be used. When only a small
number of cases is presented, the respective values or time course can be
presented individually.
(36) Data on Preterm Birth obtained from subjects receiving a vaccine should be
compared with those obtained from an appropriately selected and docu-
mented control group(s) to assess background rates of Preterm Birth in
non-exposed populations, and should be analysed by study arm and dose
where possible, e.g., in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presentation and publi-
cation of data on Preterm Birth following maternal immunisation to allow for com-
parability of data, and are recommended as an addition to data presented for the
specific study question and setting. Additionally, it is recommended to refer to
existing general guidelines for the presentation and publication of randomised con-
trolled trials, systematic reviews, and meta-analyses of observational studies in epi-ls a negative
uch an event
erring to the
ghtoncollabo-demiology (e.g., statements of Consolidated Standards of Reporting Trials
(CONSORT), of Improving the quality of reports of meta-analyses of randomised
controlled trials (QUORUM), and of Meta-analysis Of Observational Studies in Epi-
demiology (MOOSE), respectively [101–103]).
(37) All reported events of Preterm Birth should be presented according to the
categories listed in guideline 31.
(38) Data on possible Preterm Birth events should be presented in accordance
with data collection guidelines 1–24 and data analysis guidelines 31–36.
(39) Terms to describe Preterm Birth such as ‘‘low-grade”, ‘‘mild”, ‘‘moderate”,
‘‘high”, ‘‘severe” or ‘‘significant” are highly subjective, prone to wide inter-
pretation, and should be avoided, unless clearly defined.
(40) Data should be presented with numerator and denominator (n/N) (and not
only in percentages), if available.
Although immunisation safety surveillance system denominator data are usu-
ally not readily available, attempts should be made to identify approximate denom-
inators. The source of the denominator data should be reported and calculations of
estimates be described (e.g., manufacturer data like total doses distributed, report-
ing through Ministry of Health, coverage/population based data, etc.).
(41) The incidence of cases in the study population should be presented and
clearly identified as such in the text.
(42) If the distribution of data is skewed, median and range are usually the more
appropriate statistical descriptors than a mean. However, the mean and
standard deviation should also be provided.
(43) Any publication of data on Preterm Birth should include a detailed descrip-
tion of the methods used for data collection and analysis as possible. It is
essential to specify:
 The study design.
 The method, frequency and duration of monitoring for Preterm Birth.
 The trial profile, indicating participant flow during a study including
drop-outs and withdrawals to indicate the size and nature of the respec-
tive groups under investigation.
 The type of surveillance (e.g., passive or active surveillance).
 The characteristics of the surveillance system (e.g., population served,
mode of report solicitation).
 The search strategy in surveillance databases.
 Comparison group(s), if used for analysis.
 The instrument of data collection (e.g., standardised questionnaire, diary
card, report form).
 Whether the day of immunisation was considered ‘‘day one” or ‘‘day
zero” in the analysis.
 Whether the date of onset2 and/or the date of first observation3 and/or
the date of diagnosis4 was used for analysis.
 Use of this case definition for Preterm Birth, in the abstract or methods
section of a publication.11Acknowledgements
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